Establishing a Core Outcome Measure for Peritoneal Dialysis-related Peritonitis: A Standardized Outcomes in Nephrology—Peritoneal Dialysis Consensus Workshop Report

Jenny I. Shen¹, Yeoungjee Cho²,³,⁴, Karine E. Manera⁶,⁷, Fiona Brown⁸, Jie Dong⁹, Muthana Al Sahlawi¹⁰, Rafael G. Acevedo¹¹, Htay Htay¹², Yasuhiko Ito¹³, Talerngsak Kanjanabuch¹⁴, Sharon J. Nessim¹⁵, Grace Ngaruiya¹⁶, Beth Piraino¹⁷, Cheuk-Chun Szeto¹⁸, Isaac Teitelbaum¹⁹, Noa Amir⁶,⁷, Jonathan C. Craig²⁰, Amanda Baumgart⁶,⁷, Andrea M. Gonzalez⁶,⁷, Nicole Scholes-Robertson⁶,⁷, Andrea K. Viecelli²,³,⁴,⁵, Martin Wilkie²¹, Allison Tong⁶,⁷ and Jeffrey Perl²², on behalf of the SONG-PD Infection Workshop Investigators²³

¹Division of Nephrology and Hypertension, The Lundquist Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA; ²Faculty of Medicine, Department of Nephrology, Princess Alexandra Hospital, Brisbane, Queensland, Australia; ³Australasian Kidney Trials Network, Centre for Health Services Research, University of Queensland, Brisbane, Queensland, Australia; ⁴Translational Research Institute, Brisbane, Australia; ⁵University of Queensland, Brisbane, Australia; ⁶Sydney School of Public Health, The University of Sydney, Sydney, New South Wales, Australia; ⁷Center for Kidney Research, The Children’s Hospital at Westmead, Westmead, New South Wales, Australia; ⁸Department of Nephrology, Monash University at Monash Medical Centre, Melbourne, Australia; ⁹Renal Division, Department of Medicine, Peking University First Hospital, Institute of Nephrology, Peking University, Beijing, People’s Republic of China; ¹⁰Department of Internal Medicine, College of Medicine, King Faisal University, Al-Hasa, Saudi Arabia; ¹¹Renal Unit, RTS San Fernando, Cali, Colombia; ¹²Department of Renal Medicine, Singapore General Hospital, Singapore; ¹³Division of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan; ¹⁴Division of Nephrology, Department of Medicine and Center of Excellence in Kidney Metabolic Disorders, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; ¹⁵Division of Nephrology, Jewish General Hospital, McGill University, Montreal, Canada; ¹⁶School of Nursing, University of Nairobi, Nairobi, Kenya; ¹⁷University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; ¹⁸Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong, China; ¹⁹Division of Nephrology, Department of Medicine, University of Colorado, Aurora, Colorado, USA; ²⁰College of Medicine and Public Health, Flinders University, Adelaide, South Australia, Australia; ²¹Department of Nephrology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; and ²²Division of Nephrology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada

Introduction: Peritoneal dialysis (PD)-related peritonitis is one of the leading causes of discontinuation of PD and is considered a critically important outcome for patients on PD. However, there is no universally accepted method of measuring this outcome in clinical trials.

Methods: We convened an online consensus workshop to establish a core outcome measure for PD-related peritonitis in clinical trials.

Results: A total of 53 participants, including 18 patients and caregivers, from 12 countries engaged in breakout discussions in this workshop. Transcripts were analyzed thematically. We identified the following 3 themes: (i) feasibility and applicability across diverse settings, which reflected the difficulty with implementing laboratory-based measures in resource-limited environments; (ii) ensuring validity, which included minimizing false positives and considering the specificity of symptoms; and (iii) being meaningful and tangible to patients, which meant that the measure should be easy to interpret, reflect the impact that symptoms have on patients, and promote transparency by standardizing the reporting of peritonitis among dialysis units.

Conclusion: A core outcome measure for PD-related peritonitis should include both symptom-based and laboratory-based criteria. Thus, the International Society for Peritoneal Dialysis (ISPD) definition of peritonitis is acceptable. However, there should be consideration of reporting suspected peritonitis in cases where laboratory confirmation is not possible. The measure should include all infections from the time of catheter insertion and capture both the rate of infection and the number of patients who remain peritonitis free.

Correspondence: Jenny I. Shen, Division of Nephrology and Hypertension, The Lundquist Research Institute at Harbor-UCLA Medical Center, 1000 West Carson Street, Box 406, Building N28, Torrance, California 90502, USA. E-mail: jshen@lundquist.org

Received 1 December 2021; revised 26 April 2022; accepted 16 May 2022; published online 26 May 2022

Kidney International Reports (2022) 7, 1737–1744

MEETING REPORT
A core outcome measure with these features would increase the impact of clinical trials on the care and decision-making of patients receiving PD.

Kidney Int Rep (2022) 7, 1737–1744; https://doi.org/10.1016/j.ekir.2022.05.020

KEYWORDS: core outcome measure; peritoneal dialysis; peritonitis; trial design

© 2022 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

BACKGROUND

PD-related peritonitis is the most common type of PD-related infection and is a leading cause of discontinuation of PD. As the most serious type of PD-related infection, it can result in hospitalizations, permanent transfer to hemodialysis, and even death, disrupting patients’ lives with adverse emotional and physical effects.

Despite this, peritonitis is not routinely or consistently reported in studies of patients on PD. The ISPD published guidelines in 2022 which recommended that a diagnosis of peritonitis be made if at least 2 of the 3 following criteria are present: (i) clinical features consistent with peritonitis, that is, abdominal pain and/or cloudy dialysate effluent; (ii) dialysate effluent white blood cell count > 100/μl or >0.1 × 10⁹/l (after a dwell time of at least 2 hours), with >50% polymorphonuclear cells; and (iii) positive dialysate effluent culture. Yet, a systematic review of 77 studies that reported PD-related peritonitis found that in almost a third of the studies, the outcome was not even defined. The remaining studies used varying criteria to define peritonitis. Such inconsistencies make it difficult to compare the results across trials. Standardizing the measurement of PD-related peritonitis would make clinical trials more meaningful and relevant to patients, caregivers, clinicians, and other stakeholders.

PD-related infection was established as one of the critically important core outcomes to be measured in every clinical trial in PD, based on the shared priorities of >900 patients, caregivers, and health professionals from 68 countries who participated in the Standardized Outcomes in Nephrology (SONG)-PD initiative. We convened a stakeholder workshop to identify the essential features of a core outcome measure for PD-related peritonitis, the most serious infection. This workshop report summarizes the perspectives of the patients, caregivers, and health care professionals on defining a core outcome measure for PD-related peritonitis to be used in all trials of patients on PD.

SONG-PD PD-Related Peritonitis Workshop

Context and Scope

The SONG-PD PD-Related Infection Consensus Workshop was held on September 23, 2020, to establish a core outcome measure for PD-related infection. We narrowed PD-related infections to PD-related peritonitis because the feedback from the SONG-PD process was that peritonitis was the key infection patients, caregivers, and clinicians were most concerned with preventing.

The workshop was held using a Zoom video conferencing to enable broad and diverse participation.

Attendees and Contributors

The 53 workshop attendees included 18 patients and caregivers and 35 health professionals from 12 different countries (Australia, Austria, Canada, Colombia, France, Ghana, Hong Kong, Japan, Saudi Arabia, Singapore, United Kingdom, and the United States). Health professionals included nephrologists, nurses, researchers, industry representatives, and policy makers. We reached out to health professionals around the world with a variety of roles, including clinicians and researchers with a strong interest in PD, leaders in or advisors to relevant professional societies (including the ISPD), regulatory agencies (including the Centers for Disease Control in the United States), registries (Australia and New Zealand Dialysis and Transplant Registry, UK Renal Registry), and dialysis organizations. Patients and caregivers were invited by SONG-PD Infection Workshop Investigators. If invitees were unable to attend the workshop, they were asked to provide feedback before the workshop and review and add to this report as contributors. The full list of SONG-PD Infection Consensus Workshop attendees and contributors is provided in the Appendix.

Workshop Program and Materials

The workshop program is available as Supplementary File S1. Attendees and contributors received this program and background materials before the workshop. The workshop began with a brief overview of the SONG-PD process and results, the systematic review of studies on PD peritonitis, and the questions for the breakout discussions. Participants then joined 1 of 6 breakout groups, each consisted of 8 to 9 people, including 3 patients or caregivers, a facilitator, and a co-facilitator. All facilitators used the same question guide to moderate the discussion. Participants were asked whether the 2016 ISPD-recommended definition should be used for PD-related peritonitis, if the need for culture or cell count limited the feasibility of the definition, and whether the definition was relevant to patients. They also discussed whether the measure should report the
rate of peritonitis episodes alone or also include the percentage of patients affected, and at what time point the measure should start being measured.

Participants returned from the breakout discussion to join a plenary session where a representative from each group presented a summary of their discussion. The workshop chair (JP) concluded by summarizing the recommendations and key points of discussion that were made.

All the plenary and breakout sessions were audio-recorded and transcribed verbatim. The transcripts were entered into HyperRESEARCH software (version 3.7.2 m ResearchWare Inc., Randolph, MA). JIS used thematic analysis to review the transcripts line by line and inductively identify themes. The research team discussed and revised the themes to ensure that they reflected the full range and depth of the participants’ discussion on the topic. A draft workshop report was sent to attendees and contributors for feedback, and these additional comments were incorporated into the final report.

Summary of Workshop Discussion
We identified the following 3 themes that expressed the stakeholder’s perspectives on a core outcome measure for PD-related peritonitis: (i) feasibility and applicability across diverse settings; (ii) ensuring validity; and (iii) being meaningful and tangible to patients. We describe subsequently these themes and their subthemes with supporting quotations in Table 1.

Feasibility and Applicability Across Diverse Settings

Difficulty With Implementing Laboratory-Based Measures in Resource-Limited Environments. Although participants generally supported the ISPD’s recommended definition for peritonitis, there was concern that the necessity of a laboratory-based measure to make the diagnosis would make it difficult to capture PD-related peritonitis in settings where a cell count or culture was not readily accessible. Such environments include not only lower income countries but also patients in rural areas who could not easily provide a sample for testing. This limitation is particularly salient given that PD is a home modality, as opposed to in-center dialysis where laboratory resources are generally more accessible. As 1 patient expressed, “we need to make sure that we can include those people in countries that don’t have access or ready access to cell counts and cultures and such, because we’ll be losing a large number of people that would be contributing to this.” One suggestion was to “apply the ISPD criteria where a cell count and culture are available, but in areas where they aren’t, one could consider some measure called probable or suspected peritonitis based on symptoms and response to treatment alone.”

Capturing Data Relevant to Clinical, Research, and Regulatory Settings. Although the core outcome measure for PD-related peritonitis is primarily intended for clinical trials, participants felt that it should be translatable to all types of research, clinical, and regulatory settings, because the goal is to be able to “implement research into practice.” For instance, regarding the time point at which peritonitis episodes should be recorded, several participants noted that it might depend on the research question: trials focused on training might only need to capture peritonitis after training had started and trials enrolling prevalent patients were not likely to have data on episodes before enrolment. However, for both clinical and regulatory settings, attendees expressed the importance of capturing episodes from the time of PD catheter insertion to capture pretraining peritonitis. In both settings, the timing of the infection is key because it reflects what factors might be responsible; for instance, peritonitis before training would suggest that changes to perioperative practices are needed. Similarly, participants supported an outcome measure that reflects whether there were multiple infections per patient. Not only is this information needed to conduct meta-analyses, but it is also important in clinical and regulatory settings in determining whether there is a systemic (center-level) versus an individual or case-mix (patient level) issue that needs to be addressed.

“If you start seeing either a lot of cases from one patient or a lot of cases per clinic and this stands out, then obviously there’s an issue that needs to be investigated.”

Decreasing Burden of Reporting. Attendees emphasized balancing the collection of crucial information with decreasing the burden of reporting on trials. “If you load them up too much with a whole pile of measures, that actually adds trial complexity and expense.” This dampened enthusiasm for recording peritonitis-associated hospitalizations, because “then you have to talk about how many days of hospitalization, all sorts of stuff. So, it gets quite complicated.” Similarly, choosing to start data collection at the time of catheter insertion was considered simpler than starting from the end of training because “it’s much easier to collect a procedure date than first day at home.” It would be however “quite difficult” for all trials to use this start point, because “not all trials will be of patients who are just starting PD.” Furthermore, a US participant warned that it was challenging to capture peritonitis that occurs after catheter insertion and before training starts, because in the US, dialysis units are the ones that track peritonitis, and units typically do not follow patients until they start training.
### Table 1. Selected illustrative quotations for each theme

#### Feasibility and applicability across diverse settings

**Difficulty with implementing laboratory-based measures in resource-limited environments**

*“Also, people that might be like 3 hours away and solos. So, are they going to drive? Having driven and lived with peritonitis, are you going to drive 3 hours to drop a bag off? (to get laboratory-based measures)”*  
(Patient, group 1)

*“From resource constrained regions, we really have problems having positive cultures.”*  
(Health professional, group 2)

*“Certainly, for remote areas, even in Australia, I think we do encounter that issue of not being able to have a cell count within a reasonable time.”*  
(Health professional, group 3)

**Capturing data relevant to clinical, research, and regulatory settings**

*“What we’re aiming for is embedded research. So, a trial pretty much mirrors real world clinical practice. At the end of the day, whatever the trial result is, you have to actually implement it into practice. And that’s much easier if it’s just a very easy condition because it’s actually true world practice.”*  
(Health professional, group 2)

*“Thinking more from a surveillance, health care associated infection, how can we prevent infection? So, I think it’s important to know kind of when they’re occurring, throughout the spectrum, and to kind of be able to identify things that we could improve to prevent them.”*  
(Health professional, group 3)

**Decreasing burden of reporting**

*“If you load them up too much with a whole pile of measures that actually adds trial complexity and expense.”*  
(Health professional, group 2)

*“We should also be careful. I mean, this is a core outcome that we’re asking people to report. I think you can only ask them to report so many things otherwise it becomes a big burden for a trial.”*  
(Health professional, group 4)

#### Ensuring validity

**Minimizing false positives**

*“Do we want to be really sure that this is a peritonitis episode and make sure that we don’t include episodes that aren’t peritonitis, or do we want to cast a wide net and make sure we capture all of them, but also understand that we’re going to get some episodes that aren’t?”*  
(Health professional, group 1)

*“I feel if the purpose here is for really a trial setting or studies that then we would want an outcome definition that would be quite rigorous so that you could depend on the results from the study.”*  
(Health professional, group 2)

*“If every one of those episodes gets counted as an episode of peritonitis, we’re going to have counties throw their hands up, so to speak and say, ‘We’re not doing PD anymore, because our peritonitis rate is godawful!’ And I don’t think we want that. I don’t think we can have that.”*  
(Health professional, group 6)

**Specificity of signs and symptoms**

*“When I first started dialysis, it was hard to really tell what sensations I was feeling. But over time, as long as I felt the sensation and then did not see cloudy fluids within the following day or 2, I was usually pretty assured as to the lack of infection. And so, I feel that the clearest indicator, at least from a patient perspective is whether or not the solution coming out is cloudy.”*  
(Patient, group 4)

*“As with the pain, yeah. It could even just be gas sometimes; you just don’t know.”*  
(Patient, group 4)

**Distinguishing severity**

*“Knowing that getting the peritonitis episode and it actually means that you can no longer do PD. That’s a big thing for patients to know.”*  
(Patient, group 5)

*“I think 1 of the points about hospitalization though, is that in different parts of the world, the practice is different, not necessarily related to peritonitis severity, but more related just to what is standard practice in that part of the world.”*  
(Health professional, group 5)

#### Being meaningful and tangible to patients

**Reflecting the experiential relevance of symptoms and catheter insertion**

*“Patients aren’t going to have access to a lot of, for example, the testing, it’s pretty inconsequential to the patient, whether or not the cell counts match up to what the clinical definition is. Whereas, what I, as a patient, do see, or experience rather, is discomfort, pain and visually verified that the effluent is cloudy or not.”*  
(Patient, group 4)

*“I also agree about counting peritonitis from the minute the catheter is inserted into my abdomen, because that’s when I’m vulnerable. And in my mind, that’s when I started PD.”*  
(Patient, group 6)

**Ease of interpretation of the measure**

*“I would rather see it in counts as far as whole people counts, like percentages or something. It’s hard for me to understand if it would be a, the way it’s currently done sometimes, where it looks like it’s just a small [fraction] per person, I think is hard to comprehend.”*  
(Patient, group 3)

*“When you know that there is clustering of infections, I think that’s an important thing to present to patients so that they’re able to make a more informed decision without fully understanding the implications of the stats behind it.”*  
(Patient, group 4)

**Promoting transparency and education**

*“I think right now, there’s a real lack of transparency to us when we’re looking at making our choices, especially in regards to peritonitis. Patients don’t know. I’ve been asked before, ‘Does everyone get peritonitis?’ by other patients, and I don’t know if I have a real straight answer for anyone other than, ‘I hope not.’”*  
(Patient, group 3)

*“I think when you’re making a decision about what type of dialysis you’re about to start, definitely hearing the horror stories about the peritonitis is a big factor. So if you were able to clarify that it’s a smaller amount of patients that are actually getting the larger amounts of peritonitis, then it sort of shows people that really learning the proper skills and making sure that their technique while they’re doing peritonitis is the main factor in stopping that actually happening, rather than it just being a common thing that happens to people on PD.”*  
(Patient, group 5)

PD, peritoneal dialysis.

**Ensuring Validity**

**Minimizing False Positives.** Although many participants considered defining peritonitis based on just clinical features given that laboratory confirmation is not universally available, they weighed this against “increasing the likelihood of labeling something as...
peritonitis that isn’t.” As 1 participant voiced, “the purpose here is for really a trial setting, so we would want an outcome definition that would be quite rigorous so that you could depend on the results from the study.” This could have particular ramifications in the very settings where laboratory results are scarce: “If every one of these [symptom-only defined] episodes gets counted as an episode of peritonitis, we’re going to have countries throw up their hands up, so to speak, and say, ‘We’re not doing PD anymore, because our peritonitis rate is godawful.”

**Specificity of Signs and Symptoms.** Patients noted that some signs and symptoms are more specific than others. In particular, they found cloudy fluid to be fairly specific but that pain was nonspecific. One patient explained that especially when he first started PD, it was difficult to distinguish between “discomfort” or drain pain and unusual pain that might suggest peritonitis. “The key indicator to me is still the cloudiness in the effluent.” Because of this, many agreed that abdominal pain alone should not be sufficient to define peritonitis.

**Distinguishing Severity.** Attendees acknowledged that reporting the severity of an episode of peritonitis was useful because peritonitis that is severe enough to require hospitalization and discontinuation of PD has significant consequences for the patient, provider, and the health care system. As 1 patient framed it, “I’d be interested in knowing how often peritonitis leads to having to go to hemodialysis, because that’s the big decision-making part.” Others noted that because the indications for hospitalization are not standardized, hospitalization rates might not reflect the severity of the episode but rather the practice patterns of the provider. Some participants felt that because discontinuation of PD was another SONG-PD core outcome, there might be a way to integrate both measures to extrapolate which peritonitis episodes resulted in PD cessation.

**Being Meaningful and Tangible to Patients**

**Reflecting the Experiential Relevance of Symptoms and Catheter Insertion.** When considering the definition of peritonitis, patients and caregivers noted that symptoms were of paramount importance to them as these are the warning signs that they must monitor for and that trigger empirical treatment. They noted, “we only go by symptoms from the carer or the patient level” because “we can’t do all this sampling and testing, but we do know what we see.” Similarly, patients agreed that episodes should be captured starting at the time of catheter insertion, “because that’s when [they are] vulnerable. And in [their] mind, that’s when [they] started PD.”

**Ease of Interpretation of the Measure.** Participants agreed that the measure should be easy for patients and caregivers to understand. The ISPD recommends reporting peritonitis rates as episodes per patient-year at risk. However, this rate is usually a fraction of an episode per patient-year. Some patients and caregivers explained that they “would rather see it in counts as far as whole people counts, like percentages. The way it’s currently done sometimes, where it looks like it’s just a small [fraction] per person, is hard to comprehend.” They also felt that the measure should clearly express whether there were multiple infections per patient. For example, a measure that reports the percentage of patients who remained peritonitis free would “provide better context because you know there is clustering. It’s an important thing to present to patients so that they’re able to make a more informed decision without fully understanding the implications of the statistics behind it.”

**Promoting Transparency and Education.** Patients and caregivers were hopeful that standardizing the reporting of peritonitis would promote units to be more transparent about the infection rates in their programs. Patients agreed that peritonitis rates were “certainly not something that [they] heard or talked a lot about,” even though it was something they would want to know when choosing between dialysis units. Participants also considered having a measure that reflects the percentage of patients who are peritonitis free in addition to the overall rate to be essential information, because it would help patients understand that the risk of infection differs by patient. “We see that peritonitis episodes tend to cluster in about 30% or 40% of our patients. So, I think that’s relevant for caregivers and patients to know that a large subset of patients are never going to get a peritonitis episode.” This would be particularly relevant information to share with patients who are choosing a dialysis modality, because many may have only heard “horror stories about peritonitis.”
the limitation imposed by the inability to confirm using laboratory technique. However, there ultimately was no consensus that this category should be a mandatory component of the outcome measure. There was consensus that peritonitis episodes should be tracked from the time of catheter insertion, when patients start being at risk. Because the outcome measure would ideally be translatable to clinical and regulatory settings where the goal is to prevent all peritonitis, starting at a later date would be suboptimal as it would risk missing pretraining episodes. Participants also agreed that the measure should report not only the overall peritonitis rate but also the percentage of patients who remained peritonitis free. Understanding whether there is clustering of infections among patients is relevant not only for determining the etiology of the infections but also for accurately communicating the risk of infection to patients. The measure should be easily interpretable by patients and caregivers, ideally expressing risk in whole numbers rather than fractions. Although participants acknowledged that reporting the severity of an infection would be ideal, most felt that it would unduly increase the burden of reporting. Finally, patients and caregivers hoped that a standardized outcome measure for PD-related peritonitis would encourage dialysis units to be transparent in reporting their infection rates.

The ISPD updated their guidelines on peritonitis in 2022, and the workshop findings were made available to the ISPD at the time the guidelines were draft. The 2022 guidelines kept the recommended definition for PD-related peritonitis published in 2016 that had been generally considered acceptable by workshop participants. Consistent with the findings from this workshop, they recommend tracking the overall peritonitis rate and the percentage of patients per year who are peritonitis free. They suggest reporting peritonitis rates as number of episodes per patient-year. The ease of using this metric to compare rates will need to be weighed against the difficulty patients and caregivers have in interpreting risk as a fraction of an episode per patient-year. Finally, they agree with capturing peritonitis from the time of PD insertion, though they differentiate between pre-PD peritonitis which happens before the commencement of PD treatment (“i.e., first day of PD training or PD treatment in a hospital or home with the intention of continuing PD long-term, whichever occurs first”) and PD-related peritonitis, which they define as episodes that occur after PD commencement.

The workshop included patients, caregivers, clinicians, researchers, and representatives from industry and regulatory agencies globally. However, we acknowledge that a limitation of the workshop is that all the participants were English speaking and had access to videoconferencing.

Recommendations from this workshop (illustrated in Table 2) informed the establishment of a core outcome measure for PD-associated peritonitis. Although the measure is meant to standardize the reporting of clinical trials in patients on PD, participants also advocated for its use in clinical practice and research not involving trials. Collaborations with international organizations such as grant-funding agencies, clinical trial registries, and editorial boards of medical journals are ongoing to encourage its implementation. This will include working with US policymakers to adopt peritonitis as an outcome that must be reported, including episodes that occur before PD commencement. Such work is already underway as part of the Optimizing Prevention of PD-Associated Peritonitis in the US study, which aims to standardize reporting of peritonitis episodes in US dialysis clinics. The adoption of a standard, meaningful outcome measure that is consistently reported will increase the impact of trial results by simplifying the comparison and evaluation of different interventions, which will ultimately inform shared decision-making that improves the care of patients on PD.

### Table 2. Summary of workshop recommendations for establishing a core outcome measure for peritoneal dialysis-related peritonitis

| Implications for establishing a core outcome measure for PD-related peritonitis |
|-------------------------------------------------------------------------------|
| - The ISPD definition for peritonitis is generally acceptable because it incorporates both clinical features and laboratory-based measures, ensuring validity. |
| - The measure should capture both the overall rate of peritonitis and the percentage of patients who remain peritonitis free. |
| - All peritonitis episodes should be captured starting from the time of catheter insertion. (Updated in the 2022 ISPD guidelines) |
| - The measure should be easily interpretable by patients and caregivers, ideally expressing risk in whole numbers rather than fractions. |
| - Reporting suspected (vs. confirmed) peritonitis in cases where there are signs or symptoms of peritonitis, but laboratory confirmation is not possible, should be considered as in studies conducted in resource-limited environments. (Not included in 2022 ISPD guidelines) |

ISPD, International Society for Peritoneal Dialysis; PD, peritoneal dialysis.

### APPENDIX

**SONG-PD Infection Workshop Investigators**

**SONG Executive Committee.** Jonathan Craig, Allison Tong, Angela Wang, Brenda Hemmelgarn, Braden Manns, David Wheeler, John Gill, Peter Tugwell, Roberto Pecoits-Filho, Sally Crowe, Tess Harris, Wim Van Biesen, and Wolfgang Winkelmayer.

**SONG-PD Steering Group.** David W. Johnson, Angela Wang, Edwina Brown, Gillian Brunier, Jeffrey Perl, Jie Dong, Karine Manera, Martin Wilkie, Rajnish Mehrotra, Roberto Pecoits-Filho, Sue-Ann Dunning, Tony Dunning, and Yeoungjee Cho.
**SONG-PD Infection Expert Working Group.** Jeff Perl, Beth Piraino, CC Szeto, Derek Forfang, Fiona Brown, Grace Ngariuya, Htay Htay, Isaac Teitelbaum, Nicole Scholes-Robertson, Jie Dong, Rafael Gomez, Sharon Nessim, Talerngsak Kanjanabuch, Yasuhiko Ito, Jenny Shen, and Muthana Al Sahlawi.

**SONG Coordinating Committee.** Adam Martin, Amanda Baumgart, Amelie Bernier-Jean, Andrea Matus Gonzalez, Andrea Viecelli, Angela Ju, Armando Teixerapa-Pinto, Benedicte Sautenet, Camilla Hanson, Chandana Guha, Daniel Sumpton, Elyssa Hannan, Emma O’Lone, Eric Au, Jasmijn Kerklaan, Jenny Shen, Karine Manera, Louese Dunn, Martin Howell, Melissa Nataatmadja, Nicole Scholes-Robertson, Nicole Evangelidis, Noa Amir, Patrizia Natale, Rosanna Cazzolli, Samaya Anumudu, Simon Carter, Talia Gutman, Thomas Vastani Rahim Vastani, and Yeoungjee Cho.

**Participants and contributors – Health professionals.** Ali Abu-Alfa, Allison Tong, Amanda Baumgart, Andrea Matus-Gonzalez, Andrea Viecelli, Angela Wang, Benedicte Sautenet, CC Szeto, Christoph Aufricht, David W. Johnson, Elyssa Hannan, Eric Wallace, Gillian Brunier, Grace Ngariuya, Htay Htay, Indranil Dasgupta, Isaac Teitelbaum, Jeffrey Perl, Jenny Shen, John Knight, Jonathan Craig, Karine Manera, Marjorie Foo, Mark Lambie, Martin Schreiber, Martin Wilkie, Melissa Nataatmadja, Muthana Al Sahlawi, Noa Amir, Patrizia Natale, Peter Tugwell, Rafael Gomez, Roberto Pecoits-Filho, Ronal Pisoni, Ronke Apata, Sampson Antwi, Shannon Novosad, Sharon Nessim, Simon Davies, Stephanie Booth, Talerngsak Kanjanabuch, and Yasuhiko Ito.

**Participants and contributors – Patients/family members/caregivers.** Agnes Lau, Allen Chi, Barbara Heckendorn, Brandie Allen, Brenda Dewey, Danielle Horton, Dawn Edwards, Derek Forfang, Evelyn Robinson, Freddy Franco, Gary Braddock, George Grossman, Juliana Chestney, Karmen Laws, Karrin Clark, Keith Penningtong, Lisa Richardson, Nancy Verdin, Nichole Jefferson, Nicki Scholes-Robertson, Neltje Gedney, Norman Chestney, Pamela Griffiths, Sharon Kidwell, Shelley Downs, Terence Ball, Tess Harris, Thomas Yaeger, Virna Elly, and Wiliam Senior.

**DISCLOSURE**

JIS has received funding from the Canadian Institutes of Health Research outside the submitted work. HH has received speaker honoraria from Baxter Healthcare and Fresenius Medical Care and consultancy fees and travel sponsorships from AWAK Technologies Pte. Ltd., outside of the submitted work. YI received research grants or speaker honoraria from Baxter, Terumo, and JMS. TK has received consultancy fees from the VISTERRA as a country investigator and received speaking honoraria from AstraZeneca and Baxter Healthcare. SN has received speaker honoraria from Baxter Healthcare and consultancy fees from Otsuka and AstraZeneca, outside the submitted work. JP reports receiving personal fees from Baxter Healthcare, Fresenius Medical Care, Davita Healthcare Partners, DCI Inc., US Renal Care Liberi, Otsuka, and AstraZeneca, outside the submitted work. All the other authors declared no competing interests.

**ACKNOWLEDGMENTS**

The authors acknowledge, with permission, all the attendees listed subsequently who attended the consensus workshop: Health professionals: Muthana Al Sahlawi, Noa Amir, Sampson Antwi, Ronke Apata, Christoph Aufricht, Amanda Baumgart, Stephanie Booth, Gillian Brunier, Jonathan Craig, Indranil Dasgupta, Simon Davies, Marjorie Foo, Rafael Gomez, Htay, Yasuhiko Ito, David W. Johnson, Mark Lambie, Karine Manera, Andrea Matus Gonzalez, Melissa Nataatmadja, Sharon Nessim, Patrizia Natale, Shanno Novosad, Roberto Pecoits-Filho, Jeffrey Perl, Ronald Pisoni, Benedicte Sautenet, Martin Schreiber, Jenny Shen, Isaac Teitelbaum, Allison Tong, Andrea Viecelli, Eric Wallace, Angela Wang, Martin Wilkie. Patients and family members: Gary Braddock, Allen Chi, Karrin Clark, Brenda Dewey, Shelley Downs, Dawn Edwards, Derek Forfang, Neltje Gedney, Tess Harris, Barbara Heckendorn, Danielle Horton, Sharon Kidwell, Agnes Lau, Karmen Laws, Lisa Richardson, Nicole Scholes-Robertson, Nancy Verdin, Thomas Yaeger. YC is supported by a National Health and Medical Research Council Early Career Fellowship (1126256). TK is supported by the National Research Council of Thailand (156/2560) and Rachadaphisunksompong Endorsement Fund (CU-GRS_60_12_30_05), Chulalongkorn University, Thailand. JP reports receiving grants from the Agency for Healthcare Research and Quality. JIS is supported by grant K23DK103972 from the National Institutes of Health—National Institute of Diabetes and Digestive and Kidney Diseases. AT is supported by a National Health and Medical Research Council Investigator Grant (1197324). NSR is supported by a National Health and Medical Research Council Postgraduate Scholarship (ID1190850). AKV is supported by a National Health and Medical Research Council Emerging Leadership Investigator Grant (1196033). The funding organizations had no role in the study design; collection, analysis, and the interpretation of data; writing the report; and the decision to submit the report for publication.

**SUPPLEMENTARY MATERIAL**

**Supplementary File (PDF)**

File S1. SONG-PD PD-related infection consensus workshop program.
REFERENCES

1. Kolesnyk I, Dekker FW, Boeschoten EW, Krediet RT. Time-dependent reasons for peritoneal dialysis technique failure and mortality. *Perit Dial Int J Int Soc Perit Dial*. 2010;30:170–177. https://doi.org/10.3747/pdi.2008.00277

2. Mujais S, Story K. Peritoneal dialysis in the US: evaluation of outcomes in contemporary cohorts. *Kidney Int Suppl*. 2006;(103):S21–S26. https://doi.org/10.1038/sj.ki.5001912

3. ANZDATA Registry. In: 42nd Report. Adelaide, Australia: Australia and New Zealand Dialysis and Transplant Registry: 2019. Accessed August 11, 2021. http://www.anzdata.org.au

4. Campbell DJ, Craig JC, Mudge DW, et al. Patients’ perspectives on the prevention and treatment of peritonitis in peritoneal dialysis: a semi-structured interview study. *Perit Dial Int J Int Soc Perit Dial*. 2016;36:631–639. https://doi.org/10.3747/pdi.2016.00075

5. Boudville N, Kemp A, Clayton P, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. *J Am Soc Nephrol*. 2012;23:1398–1405. https://doi.org/10.1681/ASN.2011121135

6. Kumar VA, Sidell MA, Yang WT, Jones JP. Predictors of peritonitis, hospital days, and technique survival for peritoneal dialysis patients in a managed care setting. *Perit Dial Int J Int Soc Perit Dial*. 2014;34:171–178. https://doi.org/10.3747/pdi.2012.00165

7. Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. *Perit Dial Int J Int Soc Perit Dial*. 2022;42:110–153. https://doi.org/10.1177/08968608221080586

8. Sahlawi MA, Wilson G, Stallard B, et al. Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: a systematic review. *Perit Dial Int J Int Soc Perit Dial*. 2020;40:132–140. https://doi.org/10.1177/0896860819893810

9. Manera KE, Johnson DW, Craig JC, et al. Establishing a core outcome set for peritoneal dialysis: report of the SONG-PD (standardized outcomes in nephrology-peritoneal dialysis) consensus workshop. *Am J Kidney Dis*. 2020;75:404–412. https://doi.org/10.1053/j.ajkd.2019.09.017

10. Manera KE, Johnson DW, Craig JC, et al. Patient and caregiver priorities for outcomes in peritoneal dialysis: multinational nominal group technique study. *Clin J Am Soc Nephrol*. 2019;14:74–83. https://doi.org/10.2215/CJN.05380518

11. Manera KE, Tong A, Craig JC, et al. An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis. *Kidney Int*. 2019;96:699–710. https://doi.org/10.1016/j.kint.2019.03.015

12. Perl J, Fuller DS, Boudville N, et al. Optimizing peritoneal dialysis-associated peritonitis prevention in the United States: from standardized peritoneal dialysis-associated peritonitis reporting and beyond. *Clin J Am Soc Nephrol*. 2020;16:154–161. https://doi.org/10.2215/CJN.11280919